mAbs specific for surface proteins on APCs can serve as Ag-delivery vehicles that enhance immunogenicity. The practical use of such constructs is limited by the challenge of expressing and modifying full-sized mAbs. We generated single-domain Ab fragments (VHHs) specific for class II MHC (MHCII), CD11b, and CD36. VHH sequences were modified by inclusion of a C-terminal sortase motif to allow site-specific conjugation with various Ag payloads. We tested T cell activation using VHHs that target distinct APC populations; anti-MHCII adducts elicited strong activation of CD4+ T cells, whereas anti-CD11b showed CD8+ T cell activation superior to targeting via MHCII and CD36. Differences in Ag presentation among constructs were unrelated to dendritic cell subtype or routing to acidic compartments. When coupled to antigenic payloads, anti-MHCII VHH primed Ab responses against GFP, ubiquitin, an OVA peptide, and the α-helix of influenza hemagglutinin’s stem; the last afforded protection against influenza infection. The versatility of the VHH scaffold and sortase-mediated covalent attachment of Ags suggests their broader application to generate desirable immune responses.
Targeted delivery of Ags to professional APCs enhances immune responses (1–4). Covalent fusions of an anti-DEC205 mAb with an antigenic payload of interest were used for induction of CD4 and CD8 T cell responses (1, 4). Other surface proteins expressed on dendritic cells (DCs) have been exploited for similar purposes (5). However, the underlying cell biological mechanisms responsible for the efficient induction of immune responses by these means remain to be explored more fully.
Full-sized Abs can be used as fusion partners for antigenic payloads of interest, but low expression yields and structural complexity hamper the generation of such constructs. The same holds true for single-chain variable fragments derived from mAbs; these require careful design of the requisite linker to obtain stable single-chain variable fragments in adequate yield. As an alternative to this approach, we undertook the production of a smaller and simpler delivery vehicle in the form of single-domain Ab fragments (VHHs) composed of the V region of the H chain–only Abs present in camelids. VHHs, also known as single-domain Abs or nanobodies, can be expressed recombinantly in bacteria to yield proteins that retain full Ag-binding properties and lack the Fc portion of full-sized mAbs (6). Compared with classical Abs, VHHs have several advantages, including smaller size, ease of expression, monomeric behavior, and thermostability (6, 7). VHHs identified by phage display and expressed recombinantly in bacteria do not require glycosylation or disulfide bonding for Ag recognition. By reducing the size of the Ag-delivery vehicle, we also expect to improve tissue penetration.
We generated anti–class II MHC (MHCII), anti-CD11b, and anti-CD36 VHHs and analyzed their suitability as vehicles for the induction of immune responses in distinct DC populations. MHCII products, integrins (CD11b), and scavenger receptors (CD36) are abundantly expressed on APCs. Their molecular and cell biological properties are sufficiently different to warrant their exploration as possible targets for Ag delivery. The comparatively short t1/2 of VHHs in the circulation has not stood in the way of highly efficient targeting of lymphoid organs via an MHCII-specific VHH, as shown by noninvasive imaging using positron emission tomography (8). We installed a sortase-recognition site on each VHH to facilitate site-specific conjugation to Ag payloads using a modified transpeptidase, sortase A, from Staphylococcus aureus (9). The sortase-catalyzed reaction results in the installation of the substituent of interest offered as an oligo-glycine–based nucleophile (Fig. 1A). Their ease of expression in bacteria and the flexibility of the sortase platform to enable installation of structurally diverse Ags make Ag-modified VHHs an appealing strategy to enhance immune responses.
Materials and Methods
Construction of VHH library and expression of recombinant VHHs
An adult alpaca was immunized with intact unfractionated mouse splenocytes (5 × 106 cells per injection) at 2–3-wk intervals for a total of seven injections. We assessed the host response by immunoblotting of alpaca serum against membrane and cytosolic fractions of murine splenocytes that were isolated by selective plasma membrane permeabilization. Mononuclear cells from peripheral blood were isolated from the immunized alpaca by Ficoll gradient separation, followed by an established VHH library–generation protocol (10). Total RNA was extracted (RNeasy RNA Purification kit; QIAGEN), and cDNA was prepared (Superscript III First Strand Synthesis Kit; Life Technologies). The diversity of the cDNA preparation was maximized by using three sets of complementary oligonucleotides for first-strand cDNA synthesis: oligo-dT, random hexamers, and Ig-specific primers. The DNA sequences of the signal sequence from conventional and H chain–only Ig genes are not distinguishable based on the use of specific primers. However, two unique and distinct hinge regions (short and long hinge) are generated between the VHH domain and the C region (CH2). Thus, we amplified the VHH repertoire from the immune animal using alpaca VHH specific–primers that target these particular hinge sequences. The purified VHH PCR products were pooled and ligated into a phagemid vector to construct a phage display library through in-frame fusion of the amplified VHH sequences with the pIII gene of the M13 phagemid. The diversity of the phagemid library was estimated by serial dilution. The resulting VHH library consisted of ∼108 independent clones. We performed several rounds of panning against mouse splenocytes, as well as DC and B cell lines. VHH clones that showed reactivity by ELISA were enriched and expressed in WK6 Escherichia coli and grown in Terrific Broth overnight at 30°C after isopropyl β-D-thiogalactopyranoside induction (1 mM) at an OD600 of 0.6. VHHs were harvested from the periplasm by osmotic shock and purified by metal ion affinity using Ni-NTA agarose beads (QIAGEN) size-exclusion chromatography (SEC) on a Superdex 75 16/600 (GE Healthcare) in PBS or Tris HCl (50 mM [pH 7.5]).
VHH selection and immunoprecipitation assays
Expressed VHHs were sortagged to G3–Alexa Fluor 647 and buffer exchanged using PD-10 columns (GE Healthcare). To identify VHHs that recognize surface molecules on APCs, Alexa Fluor–labeled VHHs were used to costain C57BL/6 wild-type splenocytes with commercial mAbs (M5/114.15.2 anti-MHCII, eBio1D3 anti-CD19, HL3 anti-CD11c, M1/70 anti-CD11b, HM36 anti-CD36, and BM8 anti-F4/80), and they were analyzed by FACS (BD Fortessa). Cell surface molecules recognized by the selected VHHs were identified by immunoprecipitation. A20 cells were lysed with NET buffer (50 mM Tris, 0.5% Nonidet P-40, 150 mM NaCl, 5 mM EDTA [pH 7.4]) and incubated with sortagged biotinylated VHH7 for 1 h at 4°C. Cell lysates were incubated with Streptavidin beads (MyOne Dynabeads; Invitrogen) for 1 h at 4°C. MutuDCs (11) were incubated with biotinylated DC13 or DC20 VHHs for 0 or 5 min at 37°C. Cells were then lysed with NET buffer and incubated with FG beads (Tamagawa). After three rounds of washing, immunoprecipitates were analyzed by SDS-PAGE and silver stained.
All sortase reactions were performed in 50 mM Tris (pH 7.5), 150 mM NaCl, and 10 mM CaCl2 and incubated for 90 min at 15–20°C. The reagent concentrations were 100 μM VHH, 1–3 μM anti-DEC205, 500 μM nucleophile, and 2.5 μM 5M-sortase (9). Residual uncoupled substrate and sortase were removed by adsorption to Ni-NTA beads (QIAGEN). Identity of the final product, purified by gel filtration, was confirmed by SDS-PAGE and liquid chromatography–mass spectrometry (LC-MS) (Supplemental Fig. 1). All peptides used as nucleophiles were synthesized at the MIT Biopolymers & Proteomics Core Facility. (Gly)5-GFP and (Gly)5-ubiquitin were expressed in BL21(DE3) E. coli and grown in Terrific Broth overnight at 30°C after isopropyl β-D-thiogalactopyranoside induction (1 mM) at an OD600 of 0.6. Proteins were extracted using a French press and purified by metal ion affinity using Ni-NTA agarose beads (QIAGEN) SEC on a Superdex 75 16/600 (GE Healthcare) in PBS or Tris HCl (50 mM [pH 7.5]) and NaCl (150 mM). All VHH–nucleophile constructs were purified by SEC in endotoxin-free conditions.
The binding capacity of VHH7 was compared with that of two conventional fluorescent-labeled anti-MHCII mAbs: M5 (I-Ab,d,q; I-Ed,k) and AF6 (I-Ab). The mean fluorescence intensities were obtained by staining mouse splenocytes at 4°C with increasing concentrations of VHH7–Alexa Fluor 647, M5–Alexa Fluor 647, or AF6–Alexa Fluor 647. GraphPad Prism was used for curve fitting and to calculate the Ka, Kd, and KD. The affinity range is based on the observed experimental error (SE). The binding capacity of VHH7 to recombinant MHCII-CLIP variants was measured by surface plasmon resonance. KD was determined on a Biacore T100 using a Streptavidin Sensor Chip (BR100032; GE Healthcare), purified VHH7 biotinylated in a sortase A–catalyzed reaction, and different allotypic versions of fully assembled class II products in complex with class II–associated invariant chain peptide as the analyte. Ka and Kd of VHH7 were calculated for I-Ab, I-Ad, I-Au, I-Ak, and I-Ag7 and were used to determine KD. Experimental binding data were adjusted using full concentrations with local Rmax.
C57BL/6, BALB/c, μMT, Baft3-deficient, MHCII-deficient, CD11b-deficient, and CD36-deficient mice were purchased from the Jackson Laboratory, and OT-I and OT-II Rag-deficient mice were purchased from Taconic Technologies.
In vitro experiments
Splenic DCs were collected from 5–8-wk-old C57BL/6 mice and purified with CD11c or Pan-DC MACS MicroBeads (Miltenyi Biotec). Splenic DCs were activated with 1 μg/ml of anti-CD40 (1645-01; SouthernBiotech) and 12.5 μg/ml of polyinosinic-polycytidylic acid [poly(I:C)] (P0913; Sigma-Aldrich) for 1 h in RPMI 1640 (Life Technologies) supplemented with heat-inactivated fetal calf serum (IFS), washed, and incubated with VHH constructs for 45 min at different concentrations. DCs were incubated with different concentrations of chloroquine from 1 h prior to and up to 4 h after application of VHHs. After purification, all VHH constructs showed endotoxin levels < 1 EU (88282 Thermo Scientific Pierce LAL Chromogenic Endotoxin Quantitation Kit). Cells were washed and incubated with CSFE-labeled OT-I or OT-II Rag−/− T cells from transgenic mice for 18–36 h. T cells were labeled with 2 μM CFSE (Sigma-Aldrich). CD69 expression on T cells was measured 18 h after coculture, and CSFE levels of the transferred T cells were measured by FACS after 36 h of coculture to assess proliferation.
For intracellular VHH staining, splenic DCs were incubated with 1–2 μg of Alexa Fluor 647–labeled VHHs on ice for 30 min, washed, plated at 37°C for different times with 10 nM LysoTracker (Life Technologies), and incubated with anti-CD45–Alexa Fluor 488 Ab on ice (30F11; BioLegend). Cells were fixed with 4% PFA for 15 min, washed, put in solution with PBS and glycerol, imaged with a Zeiss RPI Spinning Disk microscope, and analyzed by Fiji/ImageJ.
In vivo experiments
Single-cell suspensions from spleen and lymph nodes were obtained from CD45.2 OT-I/Rag−/− or OT-II/Rag−/− transgenic mice. Cells (1 × 106) were labeled with CFSE and adoptively transferred i.v. into congenitally marked CD45.1 hosts (C57BL/6, 6–10 wk old) or derivative strains. Between 6 and 24 h after cell transfer, mice were immunized i.p. with VHH7 (0.2 μg), anti-DEC205 (1 μg), or control substrate fused to OT-II or OT-I peptide in the presence of 50 μg of poly(I:C) (P0913; Sigma-Aldrich) and 25 μg of anti-CD40 (1645-01; SouthernBiotech) in the injected solution. At days 3–7 after immunization, CD8 or CD4 T cell proliferation was measured by CFSE dilution as analyzed by flow cytometry.
BALB/c mice were left untreated or were immunized i.p. at weeks 1, 3, and 5 with equimolar amounts of VHH7 fused to payload (20–30 μg), payload alone, payload in solution with VHH7, or nucleophile fused to a control VHH. All immunizations were conducted with 25 μg of anti-CD40 and 50 μg of poly(I:C). Sera were collected at week 6 postimmunization, and Ab production was analyzed by immunoblot and ELISA.
For influenza infection, mice were anesthetized and inoculated by intranasal administration of 1.25 × 105 EID50 of purified influenza virus A H3N2/X-31 (Charles River Laboratories) in 40 μl of PBS. Body weight and survival (persistent weight loss > 25% of initial body weight) were assessed daily for 12 d postinoculation.
Mouse sera were used for immunoblotting against various concentrations of GFP, ubiquitin, OVA, or recombinant H3N2 hemagglutinin (HA) (A/Aichi/2/1968; Sino Biological). Sera were used at 1:500–3000 dilutions, and secondary Abs were used at a 1:10,000 dilution (anti-mouse IgG-HRP NXA931 [GE Healthcare], anti-His–HRP 1014992 [QIAGEN], anti-H3N2 HA 11056-MM03-50 [Sino Biological]). Quantification of densitometric traces of immunoblotted sera from immunized mice was performed with ImageJ.
Plates were coated with 5 μg of H3N2/X-31 recombinant HA (Sino Biological). Sera from mice immunized with VHH7 dimer-HA212–63 were added as serial dilutions in 0.5% IFS PBS-T for 1 h at room temperature. Plates were washed and incubated with anti-IgG1–HRP (SouthernBiotech), anti-IgG2a–HRP (SouthernBiotech), or anti-IgG2b–HRP (SouthernBiotech) at a 1:4000 dilution in 0.5% IFS PBS-T for 1 h. Plates were developed with OptEIA TMB (BD), the reaction was stopped with 1 M sulfuric acid, and the plate was read at 450 nm absorbance.
Bioengineering and characterization of VHHs
We constructed a phage display library of VHHs from an alpaca immunized with mouse splenocytes, starting with PBLs from the immunized animal, and performed several rounds of panning against mouse splenocytes, as well as against DC and B cell lines. We selected phage clones based on DNA sequences enriched for phage that were recovered on each of the target cell populations. Selected VHHs were subcloned into a bacterial expression vector, such that the resultant VHH contained the LPETG sequence as a C-terminal sortase motif, followed by a (His)6-tag to facilitate purification. The presence of the sortase motif allows coupling of any payload that carries a (Gly)3 extension at the N terminus (Fig. 1A). VHHs were expressed in the bacterial periplasm and purified using standard methods.
We selected three VHHs from the VHH library that target, but are not limited to, distinct DC populations: VHH7, which recognizes mouse MHCII products (Fig. 2) on all DC subsets; DC13, which recognizes CD11b on CD8− DCs; and DC20, specific for CD36 on CD8+ DCs (Fig. 1B, 1C) (12, 13). The targets of the individual VHHs were identified by immunoprecipitation using cell lysates prepared from DC (11) and B cell lymphoma cell lines as source material, which was followed by SDS-PAGE, silver staining, and liquid chromatography–tandem mass spectrometry of the immunoprecipitated products (Fig. 1D). To confirm the liquid chromatography–tandem mass spectrometry results, we conjugated the respective VHHs to Alexa Fluor 647 using sortase and costained splenocytes from wild-type and the corresponding knockout mice with a conventional fluorescently labeled mAb counterpart of similar specificity (Fig. 1E). The combined results established the specificity of each of the VHHs as anti-MHCII (VHH7), anti-CD11b, (DC13) and anti-CD36 (DC20).
Receptor-mediated T cell activation is independent of the DC subtype targeted
mAbs, and in particular anti-DEC205, have been used extensively to modulate immune responses (1, 14, 15). Genetic or chemical fusions of antigenic payloads with mAbs yield formulations that can elicit CD4 and CD8 T cell responses (5, 14). To test the ability of VHH7-, DC13-, and DC20-based covalent adducts to activate T cells, we used sortase to attach OT-I or OT-II peptides, the immunodominant epitopes from OVA recognized by CD8 and CD4 TCR-transgenic mice, respectively. Splenic DCs were incubated in vitro with each adduct, followed by incubation with CFSE-labeled OT-I or OT-II Rag−/− T cells for 36 h to assess T cell proliferation. OT-I/II peptides and an anti-GFP VHH (16) (Enh) were used as positive and negative controls, respectively. Although VHH7-OTI failed to induce proliferation of OT-I CD8 T cells in vitro, VHH7-OTII induced strong proliferation of OT-II CD4 T cells. This proliferation was more pronounced than that elicited by the DC13 (anti-CD11b) and DC20 (anti-CD36) adducts. However, targeting of CD11b via DC13 showed the strongest CD8 T cell activation, despite its preferred binding specificity for CD8− DCs (Fig. 3A, 3B). Because CD11b targeting showed improved cross-presentation of Ags compared with MHCII, we used fluorescently labeled VHH7 or DC13 to track the internalization of VHH–receptor complexes and acidic subcellular compartments. Despite the fact that DC13 was internalized and degraded faster than VHH7, they displayed similar rates of colocalization to acidic vesicles, as identified by LysoTracker staining. Although VHH7 reaches lysosomes later than DC13, it seems to persist longer in these compartments (Fig. 3C, 3D). To test whether a reduction in pH within lysosomes, as well as an increase in lysosomal membrane permeabilization, could enhance cross-presentation of Ags delivered by VHH7, we incubated splenic DCs with increasing concentrations of chloroquine (17, 18). Upon stimulation with 2 ng of VHH-OTI conjugates, VHH7 exhibited an expansion of OT-I T cell proliferation comparable to DC13 (Fig. 3E). However, cells treated with bafilomycin A1, to raise lysosomal pH without increasing lysosomal membrane permeabilization, did not show the same effect (data not shown), suggesting that the confinement of VHH7 in acidic compartments hinders cross-presentation of the attached Ag.
VHH7 targets CD8− DCs to activate CD4+ T cells
The VHH7-OTII adduct induces CD4 T cell proliferation in vitro. We used the same VHH7-OTII adduct to compare its capacity for Ag delivery in vitro and in vivo with that of the anti-DEC205–OTII conjugate (14). We produced VHH7-OTII, anti-DEC205–OTII, and GFP-OTII conjugates to test activation of OT-II CD4 T cells by splenic DCs. After 18 h, T cell activation was monitored by increased surface expression of CD69. On a molar basis, VHH7-OTII was more efficient at activating CD4+ T cells than were anti-DEC205–OTII and anti-GFP–OTII (Fig. 4A, 4B). We confirmed this result in vivo with CD45.1 mice that received allotypically marked CFSE-labeled CD45.2 OT-II Rag−/− T cells and that were immunized i.p. with equivalent amounts of VHH7-OTII, anti-DEC205–OTII, or GFP-OTII in combination with anti-CD40 and poly(I:C) as the adjuvant (Fig. 4C). Enhanced CD4 T cell activation by VHH7 adducts is dependent on coadministration of adjuvant; mice not immunized with adjuvant showed limited CD4 T cell activation, whereas the response was measurably stronger when adjuvants were included (Fig. 4D, 4E). The same protocol was used to compare the proliferation of transferred OT-I CD8 T cells in mice immunized with VHH7-OTI, anti-DEC205–OTI, or anti-GFP–OTI conjugates in vivo. As seen in vitro, VHH7-OTI failed to activate OT-I T cells in vivo (Fig. 4F). To identify the APCs responsible for CD4 T cell activation upon VHH7-OTII administration, we compared the proliferation of CD4+ T cells in C57BL/6 wild-type, μMT (B cell–deficient), Baft3−/− (CD8+ DC-deficient), and MHCII−/− mice. CFSE-labeled OT-II Rag−/− T cells were transferred i.v., followed by i.p. injection of VHH7-OTII or Enh-OTII in combination with anti-CD40 and poly(I:C). Because μMT and Baft3−/− mice showed results that were similar to wild-type mice, we inferred that VHH7-OTII activation of CD4+ T cells is primarily dependent on CD8− DCs (Fig. 4G, 4H).
Generation of B cell immunity against protein and peptide Ags by VHH7 delivery
Given the ability of VHH7 adducts to trigger a robust CD4 T cell response, we examined the possibility of priming Ab responses against payloads attached covalently to VHH7. As proof-of-principle, we tested the construct’s ability to trigger an immune response against GFP. For comparison, we used free Ag (GFP) or a mixture of VHH7 and free Ag at the same concentrations used for the covalent adducts. After primary immunization and two successive boosts, coadministered with poly(I:C) and anti-CD40, the presence of serum Abs was assessed in an immunoblot against GFP. Neither free GFP nor a mixture of GFP and VHH7 elicited a strong Ab response, whereas the covalent adduct did (Fig. 5A). Quantitation of the immunoblots suggested an ∼100-fold enhancement in Ab titers (Fig. 5B). Thus, increased Ab titers are readily attainable through administration of the covalently modified VHH.
We chose additional Ag models to further confirm the usefulness of VHH7 as a platform for priming robust Ab responses. We used yeast ubiquitin (96% identical to mouse) as a poorly immunogenic small protein and OVA’s OBI-17mer peptide (19), a dominant OVA B cell epitope. For the covalent VHH7–Ag conjugates tested, we observed markedly improved Ab responses. Neither the mixture of ubiquitin or OBI and VHH7, nor of Ag conjugated to a control VHH, elicited an Ab response under conditions in which the covalent conjugates were efficacious (Fig. 5C, 5D).
Dimerization of VHH7 enhances B cell immunity
Using the same expression and purification protocols, we created a genetic homodimer of VHH7 equipped with a C-terminal sortase motif (Fig. 6A, 6B) and fused it enzymatically to Alexa Fluor 647. Mice injected i.v. with fluorescent versions of VHH7 homodimer showed an ∼6-fold increase in splenocyte staining by cytofluorimetry compared with the VHH7 monomer. Fluorescence of the VHH7 dimer was detectable for up to 24 h after injection (Fig. 6C). Stained splenocytes also showed greater fluorescence intensity by microscopy (Fig. 6D, 6E). To explore whether an increase in avidity and half-life further improved Ab responses, we conjugated VHH7 dimer to OT-II and OBI peptide. Despite similar proliferation of OT-II T cells primed with monomer and dimer constructs at different concentrations (Fig. 6F), quantification of immunoblots probed with sera suggested an ∼2-fold increase in Ab titers against OVA of mice immunized with VHH7-OBI dimer relative to the monomeric form (Fig. 6G, 6H).
In vivo protection against influenza infection
We extended this immunization protocol to a sequence of influenza’s H3N2 HA2 α-helix (HA212–63) in which conserved epitopes were identified that are the target of broadly neutralizing Abs (20–23). Sera from mice immunized with the VHH7 dimer fused to the HA2 α-helix showed a strong IgG1 response against H3N2/X-31 recombinant HA by ELISA and immunoblot (Fig. 7A, 7B). To test whether this humoral response could provide immunity to influenza, we tested serum neutralization of H3N2/X-31 in vitro and challenged mice with an intranasal inoculate of the same strain (Fig. 7C). Despite a lack of virus neutralization in vitro (data not shown), the administration of HA212–63 covalently attached to VHH7 dimer improved survival and conferred protection against influenza infection.
We investigated whether targeting broadly distinct APC populations using single-domain Abs (VHHs) could be used as an Ag-delivery platform to trigger immune responses. We explored Ab responses against Ags that might otherwise be poorly immunogenic. We demonstrate that VHH7, DC13, and DC20 recognize mouse MHCII, CD11b, and CD36, respectively, and that a sortase-catalyzed reaction is an efficient means of fusing Ags to VHHs in a site-specific fashion. We show that anti-MHCII (VHH7) adducts activate CD8− DCs to elicit stronger CD4 T cell proliferation than anti-CD11b (DC13), anti-CD36 (DC20), and anti-DEC205 (14), whereas the DC13 adduct shows improved CD8 T cell proliferation. Mice immunized with VHH7 enzymatically fused to GFP, yeast ubiquitin, the OBI-17mer peptide, or the α-helix of influenza’s HA stem all elicited potent humoral responses compared with the Ag delivered in solution and simply mixed with VHH7. Ab responses were enhanced an additional ∼2-fold by a dimeric version of VHH7. Mice immunized with VHH7-H3N2 HA212–63 showed improved protection against influenza H3N2/X-31 infection. The purpose of these experiments was not so much to identify the actual DC subsets targeted but to compare the efficacy of VHH fusions that target nonoverlapping sets of APCs based on the published expression patterns of these markers. It should be emphasized that none of the molecules targeted are expressed exclusively on DCs and that, in vivo, other MHCII+, CD36+, or CD11b+ cells may contribute as well.
Abs display high selectivity and affinity and have been the preferred platform for Ag targeting. Despite the development of Ag-delivery systems that enable T cell activation, targeting approaches that enhance Ab responses need improvement (24). Pioneering work done almost three decades ago on B cell responses evoked by targeting of APCs via MHCII products showed enhanced Ab titers against avidin when administered as a noncovalent adduct with chemically biotinylated anti-MHCII mAbs (2). Other studies showed high levels of Ab responses against antigenic payloads elicited by targeting of Clec9A, CD11c, and CD180 with mAb or Fab fragments conjugated to OVA and injected into naive mice (25–27). The efficiency of these responses largely correlates with the pattern of expression of these receptors on APCs (25, 26). In the cases cited, the production of the relevant immunogens used chemical conjugation to purified mAbs, a method that is rarely site specific unless mAbs are engineered specifically for that purpose [e.g., by the introduction of a free and exposed Cys residue (28) or by making use of modifications, such as aldehyde tags (29)].
VHHs have been used extensively as neutralizing Abs (6) in the manner of conventional Abs. In this article, we show that VHHs, when equipped with a sortase motif, can be used to deliver proteins or peptides to APCs to generate humoral immunity. The use of site-specific chemical fusions can overcome many of the drawbacks of the genetic conjugation of Ags or of rather unspecific and often unpredictable chemical-modification strategies, such as maleimide- or succinimide-mediated cross-linking (30). Conventional conjugation methods and classical Abs or their derivatives are also less suited to large-scale manufacturing and high-throughput approaches (30). Sortase-catalyzed ligations have the advantage of simplicity and great flexibility in terms of the type of molecule that can be attached, whether is to a full-sized mAb (14) or an Ab fragment (8, 31). Genetic modifications of proteins by the addition of an N-terminal (Gly)n extension (with or without the use of a protease cleavage site) or the synthesis of peptides with N-terminal Gly extensions is straightforward and imposes few limits on the type of soluble Ag that can be used for ligation.
The VHH7-GFP fusion elicited an ∼100-fold increase in Ab titers, as measured by immunoblotting, compared with GFP administered alone or compared with a simple mixture of Ag with VHH7. We extended this approach to yeast ubiquitin (96% identical to mouse; 3 aa difference); OBI, an immunodominant B cell epitope (19); and the α-helical stem region of influenza HA, an accessible part of the stem where conserved epitopes that elicit broadly neutralizing Abs have been identified (20–23). A strong B cell response was recorded even when using a poorly immunogenic small protein like yeast ubiquitin or when reducing the size of the payload attached to VHH7 from a protein to a peptide, as for OBI or the HA2 α-helix. The striking difference in titers elicited by covalent VHH7-peptide fusions and the in vivo protective effect of VHH7-HA2 α-helix immunization suggest the possibility of using VHH7 to enhance immunogenicity of B cell epitopes carried by other viral, bacterial, or fungal pathogens. VHHs, by virtue of their ease of production and modification, as well as their ability to transcend the barriers imposed by genetic fusions (31), position these small Ab fragments as promising tools to (re)engineer immune responses.
We used a similar approach to deliver OT-I and OT-II epitopes in vitro to APCs. Previous studies indicated a superior ability of CD8+ DCs to activate cytotoxic T cells (32–34). In these CD8+ DCs, an intracellular environment that curtails Ag degradation and facilitates Ag transfer from endocytic compartments to the cytosol for cross-presentation may contribute to this property (35, 36). Despite the fact that the intracellular environment in CD8+ DCs is conducive to Ag cross-presentation, the efficacy of receptor-mediated Ag presentation seems to depend on other factors, such as the identity of the receptor(s) involved (37–39). In our model, the DC subset targeted, rates of receptor internalization, and routing of Ags to acidic compartments do not seem to be major determinants of the efficiency of Ag presentation. Other studies (15, 40) also suggested that the function of DC subtypes and other APCs, such as B cells (41) and macrophages (42), may overlap in their ability to initiate a CD8 T cell response. Their intrinsic characteristics and propensity to cross-present may be overshadowed by the type of surface receptor targeted. CD11b and CD36 represent molecularly quite distinct types of receptors that are expressed on CD8− and CD8+ DCs, respectively. Both are internalized in the course of phagocytosis (43). Targeting of CD11b via DC13 showed stronger proliferation of CD8+ T cells than did targeting via CD36, suggesting that, regardless of the proteolytic activity present in lysosomes, Ag presentation can still be efficient. A greater difference in CD8+ T cell proliferation was observed between CD11b and MHCII, despite the fact that both receptors are routed to acidic compartments in DCs. These differences may result, in part, from predominant targeting of MHCIIhigh DCs by VHH7, because mature DCs acidify their endocytic compartments more efficiently (44, 45).
We thank Eric Spooner (Proteomic Core Facility, Whitehead Institute) for mass spectrometry analysis and the MIT Biopolymers and Proteomics Core Facility for peptide synthesis.
This work was supported by National Institutes of Health Pioneer Award DP1-GM106409-03 and National Institutes of Health Grants R01-AI087879-06 and R01-GM100518-04 (all to H.L.P.). J.N.D. is a Calouste Gulbenkian scholar, funded by the Calouste Gulbenkian Foundation, the Champalimaud Foundation, the Portuguese Science and Technology Foundation, and the Portuguese Ministry of Health.
The online version of this article contains supplemental material.
Abbreviations used in this article:
heat-inactivated fetal calf serum
liquid chromatography–mass spectrometry
class II MHC
single-domain Ab fragment.
The authors have no financial conflicts of interest.